Don’t give in to big pharma on drug pricing | Letters
PositiveU.S News

In a recent letter, Simon Dixon argues that while drug manufacturers like Eli Lilly may criticize the UK's drug pricing, the National Health Service (NHS) should actually celebrate these prices. This perspective highlights the ongoing debate about drug affordability and access, emphasizing the importance of protecting public health interests against the pressures of big pharmaceutical companies. The discussion is crucial as it impacts how patients receive care and the sustainability of healthcare systems.
— Curated by the World Pulse Now AI Editorial System